SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), the primary physiological inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). As a member of the serpin superfamily, PAI-1 plays crucial roles in fibrinolysis regulation, extracellular matrix remodeling, and cellular signaling. Beyond its well-established functions in hemostasis and cardiovascular disease, PAI-1 has emerged as a significant contributor to neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and vascular cognitive impairment. The protein's roles in neuroinflammation, synaptic plasticity, blood-brain barrier (BBB) integrity, and protein aggregation position it as both a biomarker and therapeutic target in neurodegeneration. [1]
| Property | Value |
|---|---|
| Gene Symbol | SERPINE1 |
| Gene Name | Serpin Family E Member 1 (PAI-1) |
| Chromosomal Location | 7q22.1 |
| NCBI Gene ID | 5054 |
| OMIM | 173360 |
| UniProt | P05121 |
| Ensembl | ENSG00000105341 |
| RefSeq mRNA | NM_000321 |
| Protein Length | 402 amino acids |
Plasminogen activator inhibitor-1 is a 46 kDa glycoprotein that exists in three conformational states: active, latent, and cleaved. The active form rapidly forms covalent complexes with tPA and uPA, while the latent form represents an inactive conformation that can be converted to active by various stimuli. [1:1]
Fibrinolysis Regulation: PAI-1 inhibits tPA and uPA, limiting plasmin generation and preventing excessive fibrinolysis. This balance is critical for hemostatic equilibrium.
Extracellular Matrix Remodeling: Through modulation of the plasminogen activator system, PAI-1 influences matrix metalloproteinase (MMP) activity and tissue remodeling processes.
Cellular Signaling: PAI-1 binds to the vitronectin receptor (integrin αvβ3), promoting cell adhesion and migration. This affects angiogenesis, wound healing, and cell survival.
Senescence Regulation: PAI-1 is a downstream effector of p53-induced senescence, positioning it as a key mediator of cellular aging processes.
Within the central nervous system, PAI-1 demonstrates additional functions:
SERPINE1 is expressed in neurons, astrocytes, microglia, and endothelial cells within the brain. Basal expression is low but increases dramatically in response to inflammatory cytokines, oxidative stress, and aging. Cerebrospinal fluid PAI-1 levels are approximately 1/50th of plasma, though this ratio changes with neuroinflammation. The protein can cross the BBB in both directions under inflammatory conditions, establishing a connection between peripheral and CNS PAI-1 dynamics.
PAI-1 demonstrates multiple relationships with AD pathogenesis:
Amyloid Metabolism: PAI-1 regulates tPA-mediated plasmin generation, which degrades amyloid-beta (Aβ) peptides. Elevated PAI-1 in AD brains reduces fibrinolysis and Aβ clearance. [4]
Tau Pathology: PAI-1 expression correlates with hyperphosphorylated tau levels. The protein promotes tau aggregation and propagation through effects on extracellular proteolysis. [5]
Neuroinflammation: PAI-1 amplifies microglial activation and cytokine release. This creates a feed-forward loop where inflammation increases PAI-1, which further promotes inflammation.
Vascular Contributions: Given the vascular components of AD pathology, PAI-1's role in fibrin deposition and small vessel disease is highly relevant.
Genetic Associations: SERPINE1 polymorphisms influence AD risk and age of onset in multiple cohort studies. The 4G/5G promoter polymorphism shows variable associations.
In PD, PAI-1 exhibits complex relationships with alpha-synuclein pathology:
Alpha-Synuclein Aggregation: PAI-1 interacts with alpha-synuclein and influences its aggregation kinetics. The protein may promote oligomer formation while inhibiting fibrilization.
Dopaminergic Neuron Vulnerability: PAI-1 is elevated in the substantia nigra of PD patients, where it may contribute to dopaminergic neuron death through effects on neuroinflammation and blood-brain barrier function. [6]
Microglial Activation: The protein promotes microglial activation and migration, potentially exacerbating neuroinflammation in PD.
Oxidative Stress: PAI-1 expression is induced by oxidative stress, creating a pathogenic cycle in PD pathogenesis.
Clinical Correlations: CSF PAI-1 levels correlate with disease severity and motor symptom progression in PD patients.
SERPINE1 plays significant roles in ALS pathophysiology:
Motor Neuron Vulnerability: PAI-1 is elevated in ALS spinal cord and CSF, correlating with disease progression. The protein promotes neuroinflammation and microglial activation. [@hansen2021]
Extracellular Matrix: ALS involves significant extracellular matrix remodeling, in which PAI-1 plays a key role through effects on plasmin generation and MMP activity.
Vascular Components: Given the vascular contributions to ALS pathogenesis, PAI-1's role in blood-spinal cord barrier dysfunction is relevant.
Genetic Modifiers: SERPINE1 polymorphisms influence ALS survival and age of onset in large GWAS studies.
PAI-1 is particularly relevant to vascular contributions to cognitive decline:
Small Vessel Disease: PAI-1 promotes fibrin deposition in cerebral small vessels, contributing to vascular cognitive impairment. [7]
White Matter Damage: The protein affects white matter integrity through effects on perfusion and blood-brain barrier function.
Post-Stroke Recovery: Elevated PAI-1 impairs functional recovery after stroke through effects on plasticity and inflammation.
PAI-1 promotes neuroinflammation through multiple mechanisms:
PAI-1 contributes to BBB breakdown:
PAI-1 affects synaptic plasticity:
PAI-1 interacts with aggregation-prone proteins:
| Variant | Location | Effect | Clinical Relevance |
|---|---|---|---|
| 4G/5G | Promoter (-675) | Altered expression | Cardiovascular disease, possibly AD |
| 1100T>C (Vallle) | Exon 9 | Altered activity | Thrombosis risk |
| 3103G>A | 3'UTR | mRNA stability | May affect expression |
The 4G/5G promoter polymorphism has been extensively studied in neurodegeneration, with inconsistent results across populations and diseases.
Several PAI-1 inhibitors are in development:
Existing drugs with PAI-1 modulatory effects:
PAI-1 possesses significant biomarker utility:
Key areas for future investigation:
Teesalu et al. PAI-1 function and pathology. 2013. ↩︎ ↩︎
Brown et al. SERPINE1 and synaptic plasticity. 2021. ↩︎
Chen et al. Plasminogen activator inhibitor-1 and blood-brain barrier. 2022. ↩︎
Faut et al. PAI-1 and Alzheimer's disease pathology. 2022. ↩︎
Schwab et al. PAI-1 and tau pathology. 2020. ↩︎
Tang et al. SERPINE1 in Parkinson's disease. 2019. ↩︎
Liu et al. PAI-1 in vascular cognitive impairment. 2020. ↩︎